Gusperimus

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

390 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Gusperimus.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Gusperimus.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gusperimus.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gusperimus.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gusperimus.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gusperimus.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Gusperimus.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gusperimus.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Gusperimus.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gusperimus.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Gusperimus.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gusperimus.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gusperimus.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Gusperimus.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gusperimus.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gusperimus.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Gusperimus.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Gusperimus.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Gusperimus.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gusperimus.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Gusperimus.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gusperimus.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Gusperimus.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Gusperimus.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gusperimus.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gusperimus.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Gusperimus.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gusperimus.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Gusperimus.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Gusperimus.
Cladribine	Gusperimus may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Gusperimus.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Gusperimus.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Gusperimus.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Gusperimus.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Gusperimus.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Gusperimus.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Gusperimus.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Gusperimus.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Gusperimus.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Gusperimus.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Gusperimus.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Gusperimus.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gusperimus.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gusperimus.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Gusperimus.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Gusperimus.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Gusperimus.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Gusperimus.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Gusperimus.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Gusperimus.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Gusperimus.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Gusperimus.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Gusperimus.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Gusperimus.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Gusperimus.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Gusperimus.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Gusperimus.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Gusperimus.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Gusperimus.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Gusperimus.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Gusperimus.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Gusperimus.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Gusperimus.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Gusperimus.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Gusperimus.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gusperimus.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Gusperimus.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Gusperimus.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Gusperimus.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Gusperimus.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Gusperimus.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Gusperimus.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Gusperimus.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gusperimus.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Gusperimus.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Gusperimus.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Gusperimus.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Gusperimus.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Gusperimus.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Gusperimus.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Gusperimus.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Gusperimus.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Gusperimus.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Gusperimus.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Gusperimus.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Gusperimus.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Gusperimus.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Gusperimus.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gusperimus.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Gusperimus.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Gusperimus.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Gusperimus.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Gusperimus.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Gusperimus.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Gusperimus.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Gusperimus.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Gusperimus.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Gusperimus.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Gusperimus.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual